A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

• Status: Terminated
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

One objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. Another objective is to determine in subjects with blepharoconjunctivitis the effect of azithromycin ophthalmic solution, 1 % on markers of inflammation of lid margins and conjunctivae and on signs and symptoms of blepharoconjunctivitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Azithromycin; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Have a current diagnosis of posterior blepharoconjunctivitis in both eyes

(except for healthy volunteers)

• Have a Best Corrected Visual Acuity (BCVA), using corrective lenses if necessary, in both eyes of at least +0.7 LogMAR

• If female, are non-pregnant or non-lactating

Exclusion Criteria:

• Have anterior blepharitis

• Have lid structural abnormalities

• Have had penetrating intraocular surgery in the past 90 days or require

penetrating intraocular surgery during the study

• Unable to withhold the use of contact lenses within 3 days prior to Visit 1

during the study

• Have been diagnosed with ongoing glaucoma

• Have a serious medical condition which could confound study assessments